Cardiovascular drug delivery: A review on the recent advancements in nanocarrier based drug delivery with a brief emphasis on the novel use of magnetoliposomes and extracellular vesicles and ongoing clinical trial research

Kulkarni, Pratik; Rawtani, Deepak; Kumar, Mrityunjay; Lahoti, Swaroop R.

doi:10.1016/j.jddst.2020.102029

Cited by 16 publications

(8 citation statements)

References 107 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cardiovascular diseases have become an increasingly serious threat to human life; they are the leading cause of hospitalization and death globally [1][2][3][4][5]. Coronary artery disease (CAD), in particular, is the third most common cause of mortality worldwide, imposing a major health and economic burden on most developed nations [6][7][8][9][10][11].…”

Section: Introductionmentioning

confidence: 99%

Cardiovascular Stents: A Review of Past, Current, and Emerging Devices

et al. 2021

View full text Add to dashboard Cite

One of the leading causes of morbidity and mortality worldwide is coronary artery disease, a condition characterized by the narrowing of the artery due to plaque deposits. The standard of care for treating this disease is the introduction of a stent at the lesion site. This life-saving tubular device ensures vessel support, keeping the blood-flow path open so that the cardiac muscle receives its vital nutrients and oxygen supply. Several generations of stents have been iteratively developed towards improving patient outcomes and diminishing adverse side effects following the implanting procedure. Moving from bare-metal stents to drug-eluting stents, and recently reaching bioresorbable stents, this research field is under continuous development. To keep up with how stent technology has advanced in the past few decades, this paper reviews the evolution of these devices, focusing on how they can be further optimized towards creating an ideal vascular scaffold.

show abstract

Section: Introductionmentioning

confidence: 99%

Cardiovascular Stents: A Review of Past, Current, and Emerging Devices

et al. 2021

View full text Add to dashboard Cite

show abstract

“…This technology involves the formulation of biodegradable nanoparticles of size within the range of 1000 nm and delivering drugs and therapeutics in vivo encapsulated in these nanocarriers. Nanoparticles have shown great potential as drug carriers in several disease studies including cancer, , diabetes, , cardiovascular diseases, , AD, , and PD. , Based on composition, nanoparticles can be lipid-based, polymeric, and metallic, which can again be of various shapes, like nanovesicular, nanotube, and nanorod. Among all, nanovesicles have gathered much attention due to their vesicle-like shape, composition, and several other advantageous features as discussed below, and remarkable success has also been achieved in treatment studies of cancer, diabetes, cardiovascular diseases, and AD with the assistance of nanovesicle-aided drug delivery.…”

Section: Nanovesicle Technology: a Cutting-edge Development In Drug-d...mentioning

confidence: 99%

“…27 This technology involves the formulation of biodegradable nanoparticles of size within the range of 1000 nm and delivering drugs and therapeutics in vivo encapsulated in these nanocarriers. Nanoparticles have shown great potential as drug carriers in several disease studies including cancer, 112,113 diabetes, 24,114 cardiovascular diseases, 25,115 AD, 116,117 and PD. 118,119 Based on composition, nanoparticles can be lipidbased, polymeric, and metallic, which can again be of various shapes, like nanovesicular, nanotube, and nanorod.…”

Section: Nanovesicle Technology: a Cutting-edge Development In Drug-d...mentioning

confidence: 99%

Combating Dopaminergic Neurodegeneration in Parkinson’s Disease through Nanovesicle Technology

Roy

Paul²,

Bhattacharya

et al. 2023

ACS Chem. Neurosci.

View full text Add to dashboard Cite

Parkinson's disease (PD) is characterized by dopaminergic neurodegeneration, resulting in dopamine depletion and motor behavior deficits. Since the discovery of L-DOPA, it has been the most prescribed drug for symptomatic relief in PD, whose prolonged use, however, causes undesirable motor fluctuations like dyskinesia and dystonia. Further, therapeutics targeting the pathological hallmarks of PD including αsynuclein aggregation, oxidative stress, neuroinflammation, and autophagy impairment have also been developed, yet PD treatment is a largely unmet success. The inception of the nanovesicle-based drug delivery approach over the past few decades brings add-on advantages to the therapeutic strategies for PD treatment in which nanovesicles (basically phospholipid-containing artificial structures) are used to load and deliver drugs to the target site of the body. The present review narrates the characteristic features of nanovesicles including their blood−brain barrier permeability and ability to reach dopaminergic neurons of the brain and finally discusses the current status of this technology in the treatment of PD. From the review, it becomes evident that with the assistance of nanovesicle technology, the therapeutic efficacy of anti-PD pharmaceuticals, phyto-compounds, as well as that of nucleic acids targeting α-synuclein aggregation gained a significant increment. Furthermore, owing to the multiple drug-carrying abilities of nanovesicles, combination therapy targeting multiple pathogenic events of PD has also found success in preclinical studies and will plausibly lead to effective treatment strategies in the near future.

show abstract

“…In the Treatment of Diseases. Magnetosomes are found to be the effective carrier to deliver the drug due to its magnetic possessions [74][75][76]. In addition, the efficacy of the drug can be improved by decreasing the size of drug by using nanotechnology and eventually augment the loading dose which may offer the release of biomolecules at a constant rate to the patient and facilitate the repair of cardiac tissues [77].…”

Section: Applications Of Magnetosomesmentioning

confidence: 99%

Magnetosomes: A Tool for Targeted Drug Delivery in the Management of Cancer

Puri

Arora

Kabra

et al. 2022

Journal of Nanomaterials

View full text Add to dashboard Cite

The last two decades of developments in drug formulations and novel drug delivery systems have been seen as the beginning of a new era leading to increased patient adherence and pharmacological response to the therapeutic regimen. One of the most difficult tasks is efficiency and target-specific drug delivery or the extent of delivery at any given site of interest. Many currently designed drug delivery systems are precisely tailored to maximize the delivery of a particular form of drug by reducing the degradation or loss of the drug. In case of cancer treatment, the targeted drug delivery is of utmost importance as the anticancer agents are not having the ability to differentiate between healthy and tumor cells resulting in adverse effects and/or systemic toxicity. The targeted drug delivery is thus designed to focus on preventing side effects and encouraging the accumulation of the drug at the targeted site; one such promising drug delivery system is magnetosome drug delivery, i.e., drug delivery using magnetosomes (biological magnetic nanoparticles). In this article, we have summarized the system for design, development, and mode of drug delivery using magnetosomes along with the recent developments made in this field to facilitate the diagnosis and treatment of cancer.

show abstract

Cardiovascular drug delivery: A review on the recent advancements in nanocarrier based drug delivery with a brief emphasis on the novel use of magnetoliposomes and extracellular vesicles and ongoing clinical trial research

Cited by 16 publications

References 107 publications

Cardiovascular Stents: A Review of Past, Current, and Emerging Devices

Cardiovascular Stents: A Review of Past, Current, and Emerging Devices

Combating Dopaminergic Neurodegeneration in Parkinson’s Disease through Nanovesicle Technology

Magnetosomes: A Tool for Targeted Drug Delivery in the Management of Cancer

Contact Info

Product

Resources

About